The Prognostic Effect of Sixteen Malnutrition/inflammation-based Indicators on the Overall Survival of Chemotherapy Patients

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Mar 6

PMID 36875131

Authors

Tong Liu

Chenan Liu

Li Deng

Mengmeng Song

Shiqi Lin

Hanping Shi

Affiliations

Soon will be listed here.

Abstract

Background: Studies have confirmed the validity of malnutrition/inflammation-based indicators among cancer patients compared to chemotherapy patients. Moreover, it is necessary to identify which indicator is the best prognostic predictor for chemotherapy patients. This study attempted to determine the best nutrition/inflammation-based indicator of overall survival (OS) for chemotherapy patients.

Methods: In this prospective cohort study, we collected 16 nutrition/inflammation-based indicators among 3,833 chemotherapy patients. The maximally selected rank statistics were used to calculate the optimal values of cutoffs for continuous indicators. OS was evaluated using the Kaplan-Meier method. The associations of 16 indicators with survival were evaluated using Cox proportional hazard models. The predictive ability of 16 indicators was assessed time-dependent receiver operating characteristic curves (time-ROC) and the C-index.

Results: All indicators were significantly associated with worse OS of chemotherapy patients in the multivariate analyses (all P < 0.05). Time-AUC and C-index analyses indicated that the lymphocyte-to-CRP (LCR) ratio (C-index: 0.658) had the best predictive ability for OS in chemotherapy patients. The tumor stage significantly modified the association between inflammatory status and worse survival outcomes (P for interaction < 0.05). Compared to patients with high LCR and I/II tumor stages, patients with low LCR and III/IV tumor stages had a 6-fold higher risk of death.

Conclusions: The LCR has the best predictive value in chemotherapy patients compared with other nutrition/inflammation-based indicators.

Clinical Trial Registration: http://www.chictr.org.cn, identifier ChiCTR1800020329.

Citing Articles

The dynamics of food for special medical purposes (FSMPs) utilization in cancer care: from doctor recommendations to online pharmacy procurement.

Chereches M, Popa C, Finta H Front Pharmacol. 2024; 15:1393784.

PMID: 39119613 PMC: 11307204. DOI: 10.3389/fphar.2024.1393784.

Prognostic importance of modified geriatric nutritional risk index in oral cavity squamous cell carcinoma.

Tsai Y, Tsai M, Chang G, Tsai M, Huang E, Lu C Sci Rep. 2024; 14(1):12921.

PMID: 38839809 PMC: 11153586. DOI: 10.1038/s41598-024-63671-y.

Predicting Risk of Severe Toxicity and Early Death in Older Adult Patients Treated with Chemotherapy.

Feliu J, Custodio A, Pinto-Marin A, Higuera O, Perez-Gonzalez M, Del Pino L Cancers (Basel). 2023; 15(18).

PMID: 37760638 PMC: 10526243. DOI: 10.3390/cancers15184670.

Common nutritional/inflammatory indicators are not effective tools in predicting the overall survival of patients with small cell lung cancer undergoing first-line chemotherapy.

Tian H, Li G, Hou W, Jin J, Wang C, Ren P Front Oncol. 2023; 13:1211752.

PMID: 37576904 PMC: 10421701. DOI: 10.3389/fonc.2023.1211752.

References

Kim J, Lee J, Kim H, Wook Lee J, Jung S, Jung K . Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer. World J Gastroenterol. 2017; 23(3):505-515. PMC: 5291856. DOI: 10.3748/wjg.v23.i3.505. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Furue H . [Chemotherapy cancer treatment during the past sixty years]. Gan To Kagaku Ryoho. 2003; 30(10):1404-11. View

Guthrie G, Roxburgh C, Farhan-Alanie O, Horgan P, McMillan D . Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2013; 109(1):24-8. PMC: 3708558. DOI: 10.1038/bjc.2013.330. View

Ide S, Toiyama Y, Okugawa Y, Oki S, Yasuda H, Fujikawa H . Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery. Anticancer Res. 2017; 37(10):5797-5804. DOI: 10.21873/anticanres.12022. View

Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C . A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Int J Biol Sci. 2016; 12(8):1022-31. PMC: 4971740. DOI: 10.7150/ijbs.15438. View

Ying H, Liao Y, Sun F, Peng H, Cheng X . The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II-III Colorectal Cancer Patients After Curable Resection. J Inflamm Res. 2021; 14:115-129. PMC: 7822081. DOI: 10.2147/JIR.S285129. View

Diakos C, Charles K, McMillan D, Clarke S . Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15(11):e493-503. DOI: 10.1016/S1470-2045(14)70263-3. View

Zhang Q, Song M, Zhang X, Ding J, Ruan G, Zhang X . Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study. J Cachexia Sarcopenia Muscle. 2021; 12(6):1466-1476. PMC: 8718079. DOI: 10.1002/jcsm.12761. View

10.

Yasui K, Shida D, Nakamura Y, Ahiko Y, Tsukamoto S, Kanemitsu Y . Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients. Br J Cancer. 2020; 124(5):933-941. PMC: 7921100. DOI: 10.1038/s41416-020-01189-6. View

11.

Dolan R, McSorley S, Park J, Watt D, Roxburgh C, Horgan P . The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018; 119(1):40-51. PMC: 6035216. DOI: 10.1038/s41416-018-0095-9. View

12.

Liu C, Zhang Q, Ruan G, Shen L, Xie H, Liu T . Novel Diagnostic and Prognostic Tools for Lung Cancer Cachexia: Based on Nutritional and Inflammatory Status. Front Oncol. 2022; 12:890745. PMC: 9309732. DOI: 10.3389/fonc.2022.890745. View

13.

Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T . Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Ann Surg. 2020; 272(2):342-351. DOI: 10.1097/SLA.0000000000003239. View

14.

Suzuki S, Akiyoshi T, Oba K, Otsuka F, Tominaga T, Nagasaki T . Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer. Ann Surg Oncol. 2019; 27(3):844-852. DOI: 10.1245/s10434-019-07904-9. View

15.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W . Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017; 111:176-181. DOI: 10.1016/j.lungcan.2017.07.024. View

16.

Park J, Watt D, Roxburgh C, Horgan P, McMillan D . Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host. Ann Surg. 2015; 263(2):326-36. DOI: 10.1097/SLA.0000000000001122. View

17.

Tominaga T, Nonaka T, Hisanaga M, Fukuda A, Tanoue Y, Yoshimoto T . Prognostic value of the preoperative prognostic nutritional index in oldest-old patients with colorectal cancer. Surg Today. 2019; 50(5):449-459. DOI: 10.1007/s00595-019-01910-w. View

18.

Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kimura K . The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study. BMC Cancer. 2019; 19(1):241. PMC: 6423882. DOI: 10.1186/s12885-019-5468-9. View

19.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

20.

Xia C, Dong X, Li H, Cao M, Sun D, He S . Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022; 135(5):584-590. PMC: 8920425. DOI: 10.1097/CM9.0000000000002108. View